je.st
news
Tag: fda merck
Merck: FDA cancels panel meeting on surgery drug
2013-07-16 22:00:10| Biotech - Topix.net
Inc. said Tuesday that the Food and Drug Administration has cancelled a Thursday meeting to review its drug designed to help patients "wake up" after surgery with anesthesia.
Tags: meeting
panel
drug
surgery
Merck Statement on FDA Advisory Committee Meeting About Sugammadex Sodium Injection
2013-07-16 18:01:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, confirmed today that the U.S. Food and Drug Administration (FDA) has cancelled Thursdays discussion of sugammadex at the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC). Sugammadex sodium injection is Mercks investigational medicine for the reversal of neuromuscular blockade (NMB) induced by rocuronium or vecuronium. Language: English Contact: MerckMedia:Pam Eisele, 908-423-5042Sarra Herzog, 908-423-6154orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: statement
meeting
committee
advisory
Merck: FDA wants more studies of insomnia drug
2013-07-01 17:49:01| Biotech - Topix.net
Drugmaker Merck & Co. says federal regulators have ruled that they won't approve high doses of its experimental insomnia medication because of concerns about their safety.
FDA panel backs experimental Merck insomnia drug
2013-05-23 19:42:13| Biotech - Topix.net
A federal panel of medical experts said that an experimental insomnia drug from Merck & Co.
Tags: panel
drug
experimental
backs
Merck Statement on FDA Advisory Committee Meeting for Suvorexant
2013-05-23 00:28:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided the following statement after the conclusion of the Peripheral and Central Nervous System Drugs Advisory Committee meeting of the U.S. Food and Drug Administration (FDA) about suvorexant, Mercks investigational medicine to treat insomnia. Language: English Contact HTML: MerckMedia:Pam Eisele, 908-423-5042orTracy Ogden, 267-305-2301orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: statement
meeting
committee
advisory